Skip to main content
Evidence Snapshot

Prostaglandin E2 receptor

CHEMBL2363068 PROTEIN FAMILY Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:55Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2363068
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Prostaglandin E2 receptor as ChEMBL target CHEMBL2363068, mapped to UniProt P34995. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Prostaglandin E2 receptor
PROTEIN FAMILY · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2363068
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P34995
Prostaglandin E2 receptor EP1 subtype
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Prostaglandin E2 receptor matters

As of 2026-09-13

Prostaglandin E2 receptor is reviewed as Prostaglandin E2 receptor EP1 subtype (UniProt P34995); Prostaglandin E2 receptor shows late clinical disease relevance led by benign muscle neoplasm. 4 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded..

Protein context
Prostaglandin E2 receptor EP1 subtype

Prostaglandin E2 receptor EP1 subtype Sequence length is 402 aa.

Review this target as Prostaglandin E2 receptor, mapped to UniProt P34995. ChEMBL maps the protein component as Prostaglandin E2 receptor EP1 subtype. Sequence length is 402 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt P34995 Protein
Disease context
benign muscle neoplasm

Prostaglandin E2 receptor shows late clinical disease relevance led by benign muscle neoplasm. 4 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 4 additional disease programs remain visible in the same card. Linked drugs include DINOPROSTONE.

Start review with benign muscle neoplasm because it currently carries late clinical support. Linked drugs include DINOPROSTONE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 1 linked drug
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Prostaglandin E2 receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P34995, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why benign muscle neoplasm is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

0
Total Compounds
0
Total Assays
0
Approved Drugs
-
Activity Types

pChEMBL Activity Distribution

← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:55Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2363068